Should I Buy GNLX? GNLX 2026 Analysis

Should You Buy Genelux Corp (GNLX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.960

1 Day change

4.04%

52 Week Range

8.540

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, Genelux Corp (GNLX) is not a strong buy at the moment. The technical indicators are neutral to bearish, options data shows minimal trading sentiment, and there are no positive catalysts or financial performance data to support a long-term investment decision. For a beginner investor with a long-term strategy, this stock does not currently present a compelling opportunity.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 51.472, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 2.907, R1: 3.075, S1: 2.739, R2: 3.179, S2: 2.635.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news, no significant hedge fund or insider trading activity, and no congress trading data.

Neutral/Negative Catalysts

Bearish technical indicators, lack of trading sentiment, and no financial performance data available.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes provided.

4 Analyst Rating

Wall Street analysts forecast GNLX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.850

Low

Averages

22.5

High

Current: 2.850

Low

Averages

22.5

High

Benchmark

Speculative Buy

downgrade

$23 -> $20

AI Analysis

2026-03-20

Reason

Benchmark

Price Target

$23 -> $20

AI Analysis

2026-03-20

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Genelux to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm's sum-of-the-parts analysis for the new share count and moving the peak year assumption to 2033.

H.C. Wainwright

maintain

$31

2026-01-05

Reason

H.C. Wainwright

Price Target

$31

2026-01-05

maintain

Reason

Genelux reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/refractory lung cancer patients, outperforming historical response rates, with notable tumor shrinkage and signals of a dose-response effect at higher dosing, H.C. Wainwright tells investors in a research note. Early durability signals, including progression free survival extending to 12.1 months in one case despite single-cycle dosing and no maintenance therapy, suggest potential activity in overcoming platinum resistance, with further data expected in 2026, the firm says. H.C. Wainwright has a Buy rating and $31 price target on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GNLX

Unlock Now

GNLX Should I Buy

GNLX Should I Buy

Should You Buy Genelux Corp (GNLX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch